Corcept Therapeutics
Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CORT
Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CORT Key Statistics
Stock Snapshot
As of today, Corcept Therapeutics(CORT) shares are valued at $114.49. The company's market cap stands at 16.18B, with a P/E ratio of 273.44.
As of 2026-08-01, Corcept Therapeutics(CORT) stock has fluctuated between $111.79 and $118.53. The current price stands at $114.49, placing the stock +2.4% above today's low and -3.4% off the high.
Corcept Therapeutics(CORT) shares are trading with a volume of 1.81M, against a daily average of 1.59M.
During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $122.21 at its peak.
During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $122.21 at its peak.
CORT News
With central banks weighing their next moves, inflation signals pulling in different directions and energy prices feeding through to consumer bills, many invest...
Global markets are sending mixed signals right now. Inflation paths differ across Europe and Asia, central banks are weighing their next moves and growth indica...
Founder led companies can offer a different kind of anchor when inflation trends are mixed, central banks keep investors guessing on rates, and energy and credi...
Analyst ratings
83%
of 6 ratingsMore CORT News
With growth signals mixed across Europe, inflation still shaping central bank decisions and energy prices on every investor’s radar, leadership quality matters...
Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $165 from $88 and keeps an Overweight rating on the shares. The firm notes Corcep...
Revenue and EPS Sail Past Analyst Targets The California-based biopharmaceutical company reported second-quarter revenue of $256.1 million for the period ended...
Corcept Therapeutics (CORT) is back in focus after the FDA approved Lifyorli, its relacorilant combination for platinum resistant ovarian cancer. This developme...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.